Insider Cluster (5 insiders) ·Filed Jun 4, 2026

CORT

CORCEPT THERAPEUTICS INC
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago
Insider cluster: 5 insiders, $6.9M total
Actionable Insight • Neutral

The cluster is routine in size relative to market cap and tied to option exercises/vesting. No bearish signal. Monitor for any 8-K filings or material events that could explain the timing, but the pattern is consistent with normal portfolio diversification.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
CORT ▲ +56.09% at T+60d
NEUTRAL call ✓ call won +56.09% · α vs SPY +52.09% · entry $72.62 → $113.35
Entry anchored
Jun 4, 2026
via day open
T+1d
+0.98%
call +0.98% · α +0.75%
$73.33
settled 4mo ago
T+5d
+14.17%
call +14.17% · α +13.60%
$82.91
settled 4mo ago
T+20d
+26.15%
call +26.15% · α +24.29%
$91.61
settled 3mo ago
T+60d
+56.09%
call +56.09% · α +52.09%
$113.35
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Five Corcept Therapeutics insiders, including the CEO, CFO, and Chief Development Officer, sold a total of $6.91M in open-market shares over a 7-day window. The sales are clustered around the vesting and exercise of stock options and restricted stock units, suggesting a liquidity/planning motive rather than a coordinated bearish signal. The total value represents ~0.09% of the $7.8B market cap, which is below the 0.1% materiality threshold for insider sales.

Key Financial Metrics

Direction
selling
Total Value
$6.9M
Insiders
5

Key Facts

  • Total insider sales of $6.91M across 5 insiders in a 7-day window
  • CEO Joseph Belanoff sold $895K, CFO Atabak Mokari sold $2.80M, CDO William Guyer sold $1.41M
  • Sales coincide with option exercises and RSU vesting (non-cash grants of $0 exercise price)
  • Total sales represent ~0.09% of Corcept's $7.8B market cap
  • CEO also made a non-cash gift of 300,000 shares on May 29

Financial Impact

Total insider sales of $6.91M, or ~0.09% of market cap

insider ownership

Risk Factors

  • Insider sales could accelerate if stock continues to rise
  • CEO gift of 300K shares may precede further selling by donee

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CORT-1780606298668
26 reports for CORT
Performance horizon
100% Hit rate 7 of 7 directional calls best @ T+60▲ +63.06%Feb 24, 2026
Filters
Rows
Reports for CORT — sortable, filterable
TypeNow
Aug 28, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$113.88 $115.63▲ +1.54%▲ +1.28%$116.49 (+2.29%)
Aug 28, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$113.88 $116.10▲ +1.95%▲ +1.44%$116.49 (+2.29%)
Aug 27, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$116.93 $117.00▲ +0.06%▲ +0.16%$116.49 (−0.38%)
Aug 20, 2026
6w ago
Insider Cluster
NEUTRAL ★ 4/10
$121.05 $114.86▼ −5.11%▼ −5.11%$116.49 (−3.77%)
Aug 18, 2026
6w ago
Insider Cluster
BEARISH ★ 4/10
$118.10 $111.85▲ +5.29%▲ +4.30%$116.49 (+1.36%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$112.18 $114.92▲ +2.44%▲ +4.34%$116.49 (+3.84%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 4/10
$112.18 $114.92▲ +2.44%▲ +4.34%$116.49 (+3.84%)
Aug 6, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$110.77 $111.62▲ +0.77%▲ +1.16%$116.49 (+5.16%)
Aug 5, 2026
8w ago
Insider Cluster
NEUTRAL ★ 3/10
$107.95 $112.80▲ +4.49%▲ +3.89%$116.49 (+7.91%)
Jul 23, 2026
10w ago
Court Ruling
BULLISH ★ 4/10
$96.66 $121.05▲ +25.23%▲ +21.92%$116.49 (+20.52%)
Showing 10 of 26

US Market Status

Market Open — Closes in 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 4, 2026